Stocktoria
VivoSim Labs, INC. VIVS
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2013-08-02
VivoSim Labs, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $144,000 | $109,000 | $370,000 | $1.5M | $0 |
| R&D expense | $5.0M | $5.5M | $8.9M | $3.3M | $1.1M |
| SG&A expense | $7.7M | $9.7M | $9.2M | $9.7M | $15.7M |
| Operating income | -$12.6M | -$15.1M | -$17.7M | -$11.5M | -$16.8M |
| Income tax | $2,000 | $2,000 | $2,000 | $2,000 | $2,000 |
| Net income | -$2.5M | -$14.7M | -$17.3M | -$11.4M | -$16.8M |
| EPS (diluted) | $-1.70 | $-19.25 | $-1.98 | $-1.32 | — |
| Operating cash flow | -$9.5M | -$14.7M | -$12.4M | -$8.5M | -$13.3M |
| Free cash flow | -$9.5M | -$14.7M | -$12.8M | -$8.9M | -$13.7M |
| Cash & equivalents | $11.3M | $2.9M | $15.3M | $28.7M | $37.4M |
| Inventory | $0 | $297,000 | $0 | — | — |
| Total assets | $14.7M | $6.3M | $20.3M | $33.3M | $39.9M |
| Total liabilities | $4.2M | $2.7M | $5.0M | $3.1M | $721,000 |
| Shareholders' equity | $10.5M | $3.6M | $15.3M | $30.2M | $39.2M |
Source: SEC EDGAR filings · CIK 0001497253 · as of 2025-03-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.